FD
Schedule 13G filing
Fidelion Diagnostics Pte. Ltd. disclosed a 13.4% stake in BGLC
Fidelion Diagnostics Pte. Ltd. reported owning 13.4% of BioNexus Gene Lab Corp (BGLC) (392,329 shares) in a Schedule 13G filed Oct 22, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 22, 2026
- Source
- Schedule 13G
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.